Abstract 5216: The Effect of Erythropoietin on Restenosis in Patients With Acute Myocardial Infarction Undergoing PCI
Background: In experimental models erythropoietin not only improves myocardial function in acute myocardial infarction but also enhances reendothelialization after vessel wall injury and reduces neointima generation. Aim of this study was to analyze the angiographic restenosis in patients from the randomized, controlled Regeneration of Vital Myocardium in ST-Segment Elevation Myocardial Infarction by Erythropoietin (REVIVAL-3) study.
Methods and Results: Patients with STEMI treated with primary percutaneous coronary intervention (PCI) were randomly assigned to receive epoetin beta (3.33×104 U, n=68) or placebo (n=70) immediately, at 24 and 48 hours after PCI. Angiographic follow-up was performed after 6 months. Quantitative coronary angiography at follow-up revealed a binary restenosis rate of 12% in the erythropoietin group and 7% in the placebo group (P=0.298). In segment diameter stenosis was 32±9% in the erythropoietin group versus 26±14% in the placebo group (P=0.046). Accordingly in segment minimal lumen diameter was 2.1±0.7mm after erythropoietin as compared to 2.3±0.6 in the placebo group P=0.070).
Conclusion: In contrast to experimental findings, erythropoietin use in patients with STEMI treated with primary PCI is associated with a certain risk increase of lumen renarrowing.